EID3 and neoplasm: Among five tumor antigens identified (PTEN, EP300-interacting inhibitor of differentiation 3 (EID3), EH domain-containing protein 1, galactoside-binding soluble 9, and BRCA1-associated protein), antibody levels against the EID3 antigen were significantly higher in the patient group than in the healthy donor group, and high levels were related with shorter disease-free survival [49].